Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe Publications section now notes that PubMed publications are automatically populated and may not be about the study. The revision label changed from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check20 days agoChange DetectedNotice about government funding and NIH operating status was removed from the page's deletions section, with no changes to the study data or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check34 days agoChange DetectedThe new screenshot shows only minor user-interface adjustments, such as spacing and header alignment, with no changes to core trial information. There are no edits to the study title, conditions, interventions, eligibility criteria, enrollment, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check63 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference2%

- Check70 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

- Check85 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2; the 'Back to Top' link was removed. No substantive changes to core content, pricing, stock availability, or time-slot availability.SummaryDifference0.1%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.